Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomes

Area of Science:

• Hematologic Malignancies
• Cancer Genomics
• Molecular Oncology

Background:

• Acute myeloid leukemia (AML) is a complex blood cancer with high relapse rates.
• Understanding AML's molecular basis is crucial for effective treatment.
• Clonal evolution contributes to therapeutic challenges in AML management.

Purpose of the Study:

• To investigate genetic alterations and clonal evolution in AML patients from diagnosis to relapse.
• To correlate genetic findings with clinical outcomes in AML.
• To identify patterns of mutation acquisition and persistence in relapsed AML.

Main Methods:

• Retrospective analysis of 24 AML patients' bone marrow samples.
• Comprehensive genetic analyses: karyotyping, next-generation sequencing, gene fusion assays.
• Documentation of clinical data, treatments, and patient outcomes.

Main Results:

• Core gene mutations (FLT3, NPM1, DNMT3A, IDH2) were common at diagnosis and relapse.
• New mutations (FLT3-ITD, TP53, KIT, RUNX1, WT1) were acquired at relapse in some patients.
• Increased mutation diversity and varied clonal evolution patterns observed at relapse.

Conclusions:

• Integrated genetic analyses reveal AML heterogeneity and evolution.
• Specific mutations and clonal evolution patterns have clinical relevance.
• Personalized therapies and MRD monitoring are essential for AML management.